journal
MENU ▼
Read by QxMD icon Read
search

Annals of Oncology: Official Journal of the European Society for Medical Oncology

journal
https://www.readbyqxmd.com/read/28666313/an-update-of-the-wcrf-aicr-systematic-literature-review-and-meta-analysis-on-dietary-and-anthropometric-factors-and-esophageal-cancer-risk
#1
S Vingeliene, D S M Chan, A R Vieira, E Polemiti, C Stevens, L Abar, D Navarro Rosenblatt, D C Greenwood, T Norat
Background: In the 2007 World Cancer Research Fund/American Institute for Cancer Research Second Expert Report, the expert panel judged that there was strong evidence that alcoholic drinks and body fatness increased esophageal cancer risk, whereas fruits and vegetables probably decreased its risk. The judgments were mainly based on case-control studies. As part of the Continuous Update Project (CUP), we updated the scientific evidence accumulated from cohort studies in this topic. Methods: We updated the CUP database up to 10 January, 2017 by searching in PubMed and conducted dose-response meta-analyses to estimate summary relative risks (RRs) and 95% confidence intervals (CIs) using random effects model...
June 29, 2017: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/28666335/a-randomized-double-blind-placebo-controlled-multicenter-study-of-a-ginger-extract-in-the-management-of-chemotherapy-induced-nausea-and-vomiting-cinv-in-patients-receiving-high-dose-cisplatin
#2
P Bossi, D Cortinovis, S Fatigoni, M Cossu Rocca, A Fabi, P Seminara, C Ripamonti, S Alfieri, R Granata, C Bergamini, F Agustoni, P Bidoli, F Nolè, M A Pessi, F Macchi, L Michellini, F Montanaro, F Roila
Background: The activity of ginger in the management of chemotherapy-induced nausea and vomiting (CINV) has been suggested, but design inadequacies, heterogeneity of the population, small numbers and poor quality of tested products limit the possibility to offer generalizable results. Patients and methods: We conducted a randomized, double-blind, placebo-controlled, multicenter study in patients planned to receive ≥2 chemotherapy cycles with high dose (>50 mg/m 2 ) cisplatin...
June 28, 2017: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/28666315/lack-of-growth-inhibitory-synergism-with-combined-mapk-pi3k-inhibition-in-preclinical-models-of-pancreatic-cancer
#3
L Ciuffreda, A Del Curatolo, I Falcone, F Conciatori, C Bazzichetto, F Cognetti, V Corbo, A Scarpa, M Milella
No abstract text is available yet for this article.
June 28, 2017: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/28655213/from-academia-to-industry-a-road-more-travelled
#4
W Pao
No abstract text is available yet for this article.
June 26, 2017: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/28655197/effect-of-dose-timing-on-the-blood-concentration-of-lapatinib-in-patients-with-breast-cancer
#5
M Ohgami, H Bando, H Ishiguro, M Tsuda, N Toriguchi, K Aogi, M Toi, N Masuda, S Mitsuhashi, A Kurosawa, M Homma
No abstract text is available yet for this article.
June 26, 2017: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/28651362/possible-macrophage-activation-in-melanoma-patients-receiving-combined-kinase-inhibitor-therapy-following-anti-pd-1-therapy-a-cytokine-profiling-study-of-two-cases
#6
H Umemura, O Yamasaki, S Morizane, K Iwatsuki
No abstract text is available yet for this article.
June 23, 2017: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/28651338/evaluation-of-the-impact-of-tumor-hpv-status-on-outcome-in-patients-with-locally-advanced-unresectable-head-and-neck-squamous-cell-carcinoma-hnscc-receiving-cisplatin-5-fluorouracil-with-or-without-docetaxel-a-subset-analysis-of-eortc-24971-study
#7
A Psyrri, C Fortpied, G Koutsodontis, M Avgeris, C Kroupis, N Goutas, J Menis, L Herman, L Giurgea, E Remenar, M Degardin, I S Pateras, J A Langendijk, C van Herpen, A Awada, J R Germà-Lluch, H R Kienzer, L Licitra, J B Vermorken
Background: EORTC 24971 was a phase III trial demonstrating superiority of induction regimen TPF over PF, in terms of progression-free (PFS) and overall survival (OS) in locoregionally advanced unresectable HNSCC. We conducted a retrospective analysis of prospectively collected data aiming to evaluate whether only HPV(-) patients (pts) benefit from adding docetaxel to PF, in which case de-intensifying induction treatment in HPV(+) pts could be considered. Methods: Pre-therapy tumor biopsies (blocks or slides) were assessed for high-risk HPV by p16 immunohistochemistry, PCR and qPCR...
June 23, 2017: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/28651328/acute-coronary-syndrome-as-a-possible-immune-related-adverse-event-in-a-lung-cancer-patient-achieving-a-complete-response-to-anti-pd-1-immune-checkpoint-antibody
#8
Y Tomita, D Sueta, Y Kakiuchi, S Saeki, K Saruwatari, S Sakata, T Jodai, Y Migiyama, K Akaike, S Hirosako, K Fujisue, S Yamamura, S Miyazaki, S Takashio, Y Izumiya, K Nakamura, K Tsujita, H Ichiyasu, K Fujii
No abstract text is available yet for this article.
June 23, 2017: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/28633480/a-prospective-examination-of-circulating-tumor-cell-profiles-in-non-small-cell-lung-cancer-molecular-subgroups
#9
C R Lindsay, V Faugeroux, S Michiels, E Pailler, F Facchinetti, D Ou, M V Bluthgen, C Pannet, M Ngo-Camus, G Bescher, C Caramella, F Billiot, J Remon, D Planchard, J-C Soria, B Besse, F Farace
Background: We report the first study examining the clinical, numerical and biological properties of circulating tumor cells (CTCs) according to molecular subtypes of non-small cell lung cancer (NSCLC). Patients and Methods: 125 patients with treatment-naïve stage IIIb-IV NSCLC were prospectively recruited for CellSearch analysis. Anti-vimentin antibody was included for examination of CTCs to assess their mesenchymal character. Associations of total CTCs and vimentin-positive (vim +) CTCs with clinical characteristics, tumor genotype and survival were assessed...
June 19, 2017: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/28633466/is-complete-response-the-answer
#10
L Pusztai, B Szekely, C Hatzis
No abstract text is available yet for this article.
June 19, 2017: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/28633461/trac-erx-ing-lung-cancer-evolution
#11
S Devarakonda, R Govindan
No abstract text is available yet for this article.
June 19, 2017: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/28637287/pooled-analysis-of-two-randomized-double-blind-trials-comparing-proposed-biosimilar-la-ep2006-with-reference-pegfilgrastim-in-breast-cancer
#12
K Blackwell, P Gascon, C M Jones, A Nixon, A Krendyukov, R Nakov, Y Li, N Harbeck
NCT01735175, NCT01516736.
June 16, 2017: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/28637247/surgery-for-patients-with-lower-grade-glioma-putting-assumptions-beliefs-and-convictions-into-perspective
#13
Michael Weller
No abstract text is available yet for this article.
June 16, 2017: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/28637281/pulmonary-sarcomatoid-carcinoma-a-new-hope
#14
J M Boland, A S Mansfield, A C Roden
No abstract text is available yet for this article.
June 15, 2017: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/28633425/androgen-receptor-mutations-in-patients-with-castration-resistant-prostate-cancer-treated-with-apalutamide
#15
D E Rathkopf, M R Smith, C J Ryan, W R Berry, N D Shore, G Liu, C S Higano, J J Alumkal, R Hauke, R F Tutrone, M Saleh, E Chow Maneval, S Thomas, D S Ricci, M K Yu, C J de Boer, A Trinh, T Kheoh, R Bandekar, H I Scher, E S Antonarakis
Background: : Mutations in the androgen receptor (AR) ligand-binding domain (LBD), such as F877L and T878A, have been associated with resistance to next-generation AR-directed therapies. ARN-509-001 was a phase I/II study that evaluated apalutamide activity in castration-resistant prostate cancer (CRPC). Here we evaluated the type and frequency of 11 relevant AR-LBD mutations in apalutamide-treated CRPC patients. Patients and methods: : Blood samples from men with non-metastatic CRPC (nmCRPC) and metastatic CRPC (mCRPC) pre- or post abiraterone acetate and prednisone (AAP) treatment (≥6 months' exposure) were evaluated at baseline and disease progression in trial ARN-509-001...
June 15, 2017: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/28633409/the-effect-of-pd-l1-testing-on-the-cost-effectiveness-and-economic-impact-of-immune-checkpoint-inhibitors-for-the-second-line-treatment-of-nsclc
#16
P N Aguiar, L Perry, J Penny-Dimr, H Babiker, H Tadokoro, R A de Mello, G L Lopes
Background: Immune checkpoint inhibitors improve outcomes compared to chemotherapy in lung cancer. Tumor PD-L1 receptor expression is being studied as a predictive biomarker. The objective of this study was to assess the cost-effectiveness and economic impact of second-line treatment with nivolumab, pembrolizumab, and atezolizumab with and without the use of PD-L1 testing for patient selection. Design: We developed a decision-analytic model to determine the cost-effectiveness of PD-L1 assessment and second-line immunotherapy versus docetaxel...
June 15, 2017: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/28633362/human-papillomavirus-related-oropharyngeal-cancer
#17
M Taberna, M Mena, M A Pavón, L Alemany, M L Gillison, R Mesía
High-risk (HR) human papillomavirus (HPV) is now recognised as the principal cause of the increasing incidence rates of oropharyngeal squamous cell carcinoma (OPSCC) in some parts of the world.The primary risk factor for developing HPV-related OPSCC is oral HPV-infection and the majority of oral HPV-infections are acquired by oral sex. Progression into a OPSCC includes persistent infection with evasion of immune response in the microenvironment, the activation of viral early genes (E6, E7) in basal epithelial cells, the deregulation of cell cycle and the accumulation of chromosomal instability...
June 15, 2017: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/28633343/an-unknown-reaction-to-pembrolizumab-giant-cell-arteritis
#18
I Micaily, M Chernoff
No abstract text is available yet for this article.
June 15, 2017: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/28633365/phase-ii-study-of-copanlisib-a-pi3k-inhibitor-in-relapsed-or-refractory-indolent-or-aggressive-lymphoma
#19
M Dreyling, F Morschhauser, K Bouabdallah, D Bron, D Cunningham, S E Assouline, G Verhoef, K Linton, C Thieblemont, U Vitolo, F Hiemeyer, M Giurescu, J Garcia-Vargas, I Gorbatchevsky, L Liu, K Koechert, C Peña, M Neves, B H Childs, P L Zinzani
Background: Copanlisib is a pan-class I phosphatidylinositol 3-kinase (PI3K) inhibitor with predominant activity against the α- and δ- isoforms. Patients and methods: This phase II study evaluated the response rate of copanlisib administered intravenously on days 1, 8, and 15 of a 28-day cycle, in patients with indolent or aggressive malignant lymphoma. Archival tumor tissues were used for immunohistochemistry, gene-expression profiling, and mutation analysis...
June 14, 2017: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/28595336/changes-in-serum-interleukin-8-il-8-levels-reflect-and-predict-response-to-anti-pd-1-treatment-in-melanoma-and-non-small-cell-lung-cancer-patients
#20
M F Sanmamed, J L Perez-Gracia, K A Schalper, J P Fusco, A Gonzalez, M E Rodriguez-Ruiz, C Oñate, G Perez, C Alfaro, S Martín-Algarra, M P Andueza, A Gurpide, M Morgado, J Wang, A Bacchiocchi, R Halaban, H Kluger, L Chen, M Sznol, I Melero
Background: HASH(0x4dfc1f8) Patients and methods: HASH(0x4dfc4e0) Results: HASH(0x4df6a40) Conclusions: HASH(0x4df07d0)
June 8, 2017: Annals of Oncology: Official Journal of the European Society for Medical Oncology
journal
journal
30452
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"